Non-systemic TGR5 agonists

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• each X1 is independently CH or N;
• R1 and R2 are each independently H, halogen, C1-6alkyl, C1-6alkoxy, CN, NO2 or NH2, wherein alkyl is optionally substituted with 1-4 halogen;
• each optionally mono-, di-, or tri-substituted with substituents independently selected from halogen and C1-3alkyl, wherein alkyl is optionally substituted with 1-4 halogen;
• R3 is H,
• R4 and R5 are each independently H, C1-6alkyl, phenyl, C1-6alkyl-OH, C1-6alkyl-CN, C1-6alkyl-NH2, C0-6alkylC(O)OC1-6alkyl, C0-6alkylC(O)OH, C0-6alkylC(O)NHC1-6alkyl, C0-6alkylC(O)N(C1-6 alkyl) (C1-6alkyl), C0-6alkylC(O)NHC1-6alkylS(O)2OH or C0-6alkylNHC(O)NHC1-6alkylS(O)2OH,
• or R4 and R5 together with the C to which they are attached form oxetanyl;
• each X2 is independently CH or N, and no more than one X2 can be N;
• R6 is halogen, C1-6alkyl, C1-6alkoxy, OH or OC1-6alkyl-C(O)OH;
• A is
• each optionally mono-, di-, or tri-substituted with substituents independently selected from halogen, C1-3alkyl, C1-3alkoxy, OC1-3alkylOC1-3alkyl, C1-3alkylOH, OH, NH2, N(C1-3alkyl)(C1-3alkyl), C(O)N(C1-3alkyl)(C1-3alkyl), NC(O)C1-3alkyl, C(O)OC1-3alkyl and C1-3alkylC(O)NHC1-3alkylS(O)2OH, wherein alkyl is optionally substituted with 1-4 halogen;
• each L is independently absent,
• T is NH2, NH(C1-6alkyl), NH(C1-6alkyl)(C1-6alkyl),
• each n is independently 0, 1, 2, 3, 4 or 5, and at least one n is not 0;
• each R is chosen from hydrogen, C1-3alkyl, C1-3alkyl-OH and C0-3alkyl-C(O)OH;
• and
• each X is independently CH or N, and no more than two X can be N.